Larvol Delta - Selective-Oral-AURKA-Inhibitor-Treatment-for-GraftVersusHost-Disease-and-Relapse-Prophylaxis-Following-Allogeneic-HCT-Singlearm-Phase-1-Dose-Escalation-Trial--

sirolimus (STN1010904) - Santen, ActualEyes

VIC-1911 - VITRAC Therap

Cyrevia (cyclophosphamide high dose) - Accentia

https://www.hmpgloballearningnetwork.com/site/onc/conference-coverage/selective-oral-aurka-inhibitor-treatment-graft-versus-host-disease-and

Dec 21, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next